|
|
News Breaks | | | | November 26, 2012 | | 05:09 EDT |  | PHARM | Pharming Group announces receipt of $10M milestone payment
Biotech company Pharming Group announced that following the announcement by Pharming and Santarus on November 7 that the pivotal Phase III clinical study of Ruconest, a recombinant human C1 esterase inhibitor, 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema met its primary endpoint, and in accordance with the terms of the license agreement between Pharming and Santarus, a $10M milestone has now been paid to Pharming. An additional $5M milestone will be payable to Pharming upon FDA acceptance of the Biologics License Application, or BLA, for review. Pharming and Santarus expect to submit the BLA for Ruconest to the FDA in the first half of 2013. | |
|
News For PHARM From The Last 14 Days Check below for free stories on PHARM the last two weeks. |
|
|
| There are no results for PHARM |
|
|
|
|
|
|
